Benign prostatic hyperplasia: Now we can begin to tailor treatment

Article Type
Changed
Mon, 10/08/2018 - 15:51
Display Headline
Benign prostatic hyperplasia: Now we can begin to tailor treatment
Article PDF
Author and Disclosure Information

Carl K. Gjertson, MD
Department of Urology, College of Physicians and Surgeons, Columbia University, New York

Konstantin Walmsley, MD
Department of Urology, College of Physicians and Surgeons, Columbia University, New York

Steven A. Kaplan, MD
Department of Urology, College of Physicians and Surgeons, Columbia University, New York

Address: Steven A. Kaplan, MD, Department of Urology, College of Physicians and Surgeons, Columbia University, Irving Pavilion, 11th floor, 161 Fort Washington Avenue, New York, NY 10032; e-mail [email protected]

Dr. Kaplan has indicated that he has received grant or research support from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and that he is on the speakers’ bureaus of the Merck, Glaxo, Boehringer Ingelheim, and Sanofi corporations.

Issue
Cleveland Clinic Journal of Medicine - 71(11)
Publications
Topics
Page Number
857, 860, 863-865, 869-870, 872-873, 877-878, 880
Sections
Author and Disclosure Information

Carl K. Gjertson, MD
Department of Urology, College of Physicians and Surgeons, Columbia University, New York

Konstantin Walmsley, MD
Department of Urology, College of Physicians and Surgeons, Columbia University, New York

Steven A. Kaplan, MD
Department of Urology, College of Physicians and Surgeons, Columbia University, New York

Address: Steven A. Kaplan, MD, Department of Urology, College of Physicians and Surgeons, Columbia University, Irving Pavilion, 11th floor, 161 Fort Washington Avenue, New York, NY 10032; e-mail [email protected]

Dr. Kaplan has indicated that he has received grant or research support from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and that he is on the speakers’ bureaus of the Merck, Glaxo, Boehringer Ingelheim, and Sanofi corporations.

Author and Disclosure Information

Carl K. Gjertson, MD
Department of Urology, College of Physicians and Surgeons, Columbia University, New York

Konstantin Walmsley, MD
Department of Urology, College of Physicians and Surgeons, Columbia University, New York

Steven A. Kaplan, MD
Department of Urology, College of Physicians and Surgeons, Columbia University, New York

Address: Steven A. Kaplan, MD, Department of Urology, College of Physicians and Surgeons, Columbia University, Irving Pavilion, 11th floor, 161 Fort Washington Avenue, New York, NY 10032; e-mail [email protected]

Dr. Kaplan has indicated that he has received grant or research support from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and that he is on the speakers’ bureaus of the Merck, Glaxo, Boehringer Ingelheim, and Sanofi corporations.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 71(11)
Issue
Cleveland Clinic Journal of Medicine - 71(11)
Page Number
857, 860, 863-865, 869-870, 872-873, 877-878, 880
Page Number
857, 860, 863-865, 869-870, 872-873, 877-878, 880
Publications
Publications
Topics
Article Type
Display Headline
Benign prostatic hyperplasia: Now we can begin to tailor treatment
Display Headline
Benign prostatic hyperplasia: Now we can begin to tailor treatment
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media